New drug shrinks tumors in Hard-to-Treat bladder cancer
NCT ID NCT04995419
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested enfortumab vedotin, a drug that delivers chemotherapy directly to cancer cells, in 40 Chinese patients with advanced bladder cancer that had worsened after standard treatments. The main goal was to see how many patients' tumors shrank. The trial also looked at how long the effect lasted and how safe the drug was. Results help determine if this drug is a good option for this patient group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
enfortumab vedotin (PADCEV)
What this could lead to
If successful, this could provide a new treatment option for Chinese patients with advanced bladder cancer who have run out of standard therapies.
What could go wrong
This is a small, early-phase study with only 40 participants. The drug may cause side effects like nerve damage or skin reactions, and not all patients responded.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UROTHELIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site CN86001
Beijing, China
-
Site CN86002
Guangzhou, China
-
Site CN86003
Wuhan, China
-
Site CN86004
Shanghai, China
-
Site CN86006
Hangzhou, China
-
Site CN86007
Nanjing, China
-
Site CN86009
Changsha, China